Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

42. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort Paul Kwo, 1 Michael W. Fried, 2 K. Rajender Reddy, 3 Consuelo Soldevila-Pico, 4 Saro Khemichian, 5 Jama (...) Darling, 2 Phillippe J. Zamor, 6 Andrew A. Napoli, 7 Beatrice Anduze-Faris, 7 and Robert S. Brown Jr. 8 We report the ?ndings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced ?brosis/cirrhosis. Patients had LLOQ at any posttreatment visit after HCV RNA 10

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

43. Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis Changes in Natural Killer Cells and Exhausted Memory Regulatory T Cells With Corticosteroid Therapy in Acute Autoimmune Hepatitis Hannah C. Jeffery, 1 Manjit K. Braitch, 1 Chris Bagnall, 2 James Hodson, 3 Louisa E. Jeffery, 1 Rebecca E. Wawman, 1,4 Lin Lee Wong, 5 Jane Birtwistle, 6 Helen Bartlett, 1 Ansgar W. Lohse, 7 Gideon M. Hirsch?eld, 1,8 Jessica Dyson, 5 David (...) Jones, 5 Stefan G. Hubscher, 1,9 Paul Klenerman, 10 David H. Adams , 1,8 and Ye H. Oo 1,8 Autoimmune hepatitis (AIH) is an immune-mediated liver disease currently treated by immunosuppressive medications with signi?cant side effects. Thus, novel mechanistic treatments are greatly needed. We performed prospective deep immunophenotyping of blood immune cells in patients with acute AIH before and after corticosteroid therapy. Blood samples from 26 patients with acute AIH (United Kingdom-AIH Consortium

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

44. New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome

New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome - Zhang - 2018 - Hepatology Communications - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search Original Article Open Access New scoring classification for primary biliary cholangitis–autoimmune hepatitis (...) . Louis, MO Department of Pathology, Saint Louis University School of Medicine, St. Louis, MO Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, College of Medicine, Gainesville, FL Corresponding Author E-mail address: Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO Saint Louis University Liver Center, St Louis, MO ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO : Bruce R. Bacon, M.D. 3635 Vista Avenue at Grand Blvd

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

45. Occult Hepatitis C Virus Infection: A Review

Occult Hepatitis C Virus Infection: A Review Review Article OccultHepatitisCVirusInfection:AReview Alyssa Austria* and George Y. Wu Division of Gastroenterology-Hepatology, Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA Abstract OcculthepatitisCvirus(HCV)infection(OCI),firstdescribedin 2004,isdefinedasthepresenceofHCVRNAinhepatocytesor peripheral blood mononuclear cells without detectable HCV RNAintheserum.Here,weaimedtoreviewtheepidemiology (...) , diagnostic methods, clinical implications and potential man- agement recommendations currently described in the litera- ture, as well as the future directions for investigation of this entity. PubMed and Cochrane databases were searched with combination of the following keywords: “occult”, “hepatitis C virus”,and “occult HCV infection”. There are data to support OCIasapotentialculpritincryptogenicliverdisease.Thereare also consistent data demonstrating the existence of OCI in specific populations

Journal of clinical and translational hepatology2018 Full Text: Link to full Text with Trip Pro

46. Animal models for the study of hepatitis B virus infection

Animal models for the study of hepatitis B virus infection 29511142 2018 04 13 2018 11 14 2095-8137 39 1 2018 Jan 18 Zoological research Zool Res Animal models for the study of hepatitis B virus infection. 25-31 10.24272/j.issn.2095-8137.2018.013 Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus (HBV) worldwide. Current antiviral therapies, including interferon and nucleot(s)ide analogues, rarely cure chronic hepatitis B. Animal (...) models are very crucial for understanding the pathogenesis of chronic hepatitis B and developing new therapeutic drugs or strategies. HBV can only infect humans and chimpanzees, with the use of chimpanzees in HBV research strongly restricted. Thus, most advances in HBV research have been gained using mouse models with HBV replication or infection or models with HBV-related hepadnaviral infection. This review summarizes the animal models currently available for the study of HBV infection. Guo Wei-Na

Zoological research2018 Full Text: Link to full Text with Trip Pro

47. Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues Elucidating the Differences in Pathogenicity Between Hepatitis E Virus Genotypes: The Quest Continues SEE ARTICLE ON PAGE 173 H epatitis E virus (HEV) is an emerging path- ogen and the most common cause of acute hepatitis. (1) Five genotypes have been described to be capable of infecting humans (genotype 1, gt2, gt3, gt4, and gt7), and two genotypes (gt5 and gt6) have been described that only (...) affect other ani- mals. (1) HEV typically causes an acute self-limiting ill- ness, and not all infections develop overt clinical signs. After an incubation period of 2 to 6 weeks, nonspeci?c symptoms, such as fever, nausea, abdominal pain, vomiting,anorexia,jaundice,andmalaise,candevelop. Excess mortality can be seen in individuals with an underlying chronic liver disease, in immunosuppressed patients, and in pregnant women. HEV infection dur- ing pregnancy can take a fulminant course, resulting

Hepatology communications2018 Full Text: Link to full Text with Trip Pro

48. Peginterferon alfa-2a (Pegasys) - Treatment of hepatitis B

Peginterferon alfa-2a (Pegasys) - Treatment of hepatitis B Published 12 February 2018 Statement of Advice peginterferon alfa-2a 135 micrograms and 180 mcrograms solution for injection in pre-filled pen / peginterferon alfa-2a 90 micrograms, 135 micrograms and 180 micrograms solution for injection in pre-filled syringe (Pegasys ® ) SMC No 1312/18 Roche Products Ltd 12 January 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation peginterferon alfa-2a (Pegasys (...) ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may

Scottish Medicines Consortium2018

50. Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management

Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management | Clinical Correlations Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management January 31, 2018 Podcast: | Subscribe: | By Amy Shen Tang MD, Marty Fried MD and Shreya P. Trivedi MD; Illustration by Michelle Lo, MD & Amy Ou, MD. Quiz yourself on the following 5 Pearls on Chronic Hepatitis B (HBV) Management Time Stamps What is the focused history, physical and lab workup (...) in a patient with chronic HBV? ( 1:40) What is the best imaging to evaluate for intermediate stages of liver fibrosis? ( 4:06) What scoring tools can you use to estimate fibrosis and what are their limitations? What factors do you use to assess which patients get treatment ? ( 7:41) What drugs are available for HBV treatment and how do you choose? ( 11:18) Which chronic HBV patient should be screened for HCC , and how often? ( 14:45) Follow us on Facebook || Twitter || Instagram . Subscribe to CORE IM

Clinical Correlations2018

51. Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling

Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Assessing the impact (...) and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Platt L, Sweeney S, Ward Z, Guinness L, Hickman M, Hope V, Hutchinson S, Maher L, Iversen J, Craine N, Taylor A, Munro A, Parry J, Smith J & Vickerman P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

Health Technology Assessment (HTA) Database.2018

52. [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 (...) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir/velpatasvir/ voxilaprevir (chronische

Health Technology Assessment (HTA) Database.2018

53. [Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C) – benefit assessment according to §35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C (...) ) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V

Health Technology Assessment (HTA) Database.2018

54. [Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V]

[Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis C) – benefit assessment according to § 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis (...) C) – benefit assessment according to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V

Health Technology Assessment (HTA) Database.2018

55. HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine

HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset (...) password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × December 2017. Volume 13. Number 4 HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s

Evidencias en Pediatría2018

56. [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to §35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit (...) assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55

Health Technology Assessment (HTA) Database.2018

57. Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies

Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies Review Article CardiovascularInvolvementinChronicHepatitisCVirus Infections–InsightfromNovelAntiviralTherapies Wolfgang Poller* 1,2 , Arash Haghikia 1,2 , Mario Kasner 1 , Ziya Kaya 3,4 , Udo Bavendiek 5 , Heiner Wedemeier 6 , Hans-Jörg Epple 7 , Carsten Skurk 1 and Ulf Landmesser 1,2 1 Department of Cardiology, CC11 Charité Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin (...) Berlin, Berlin, Germany Abstract Whereas statistical association of hepatitis C virus (HCV) infection with cardiomyopathy is long known, establishment ofacausalrelationshiphasnotbeenachievedsofar.Patients withadvancedheartfailure(HF)aremostlyunabletotolerate interferon(IFN)-basedtreatment, resultingin limitedexperi- ence regarding the possible pathogenic role of HCV in this patientgroup.HCVinfectionoftentriggersdiseaseinabroad spectrum of extrahepatic organs, with innate immune and autoimmune

Journal of clinical and translational hepatology2018 Full Text: Link to full Text with Trip Pro

58. Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle of Hepatitis E Virus

Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle of Hepatitis E Virus Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle of Hepatitis E Virus | mSystems Main menu User menu Search Search for this keyword Search for this keyword Research Article | Host-Microbe Biology Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle (...) of Hepatitis E Virus Chandru Subramani , Vidya P. Nair , Saumya Anang , Sukhen Das Mandal , Madhu Pareek , Nidhi Kaushik , Akriti Srivastava , Sudipto Saha , Shalimar , Baibaswata Nayak , C. T. Ranjith-Kumar , Milan Surjit David M. Knipe , Editor Chandru Subramani Virology Laboratory, Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad, Haryana, India Vidya P. Nair Virology

mSystems2018 Full Text: Link to full Text with Trip Pro

59. Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association

Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association DOI: 10.5152/eurjrheum.2018.17135 Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association Introduction In systemic lupus erythematosus (SLE), the musculoskeletal manifestations are the most frequent man- ifestations, arthritis and arthralgias being the most common. Myalgias and muscular (...) weakness are not uncommon, while inflammatory myopathies and polymyositis in particular are less frequent. Apart from the overlap with authentic inflammatory myopathies, cases of steroid myopathy, hydroxychloroquine-in- duced myopathy, and even vacuolar myopathy, have been reported (1). Digestive manifestations are less frequent in SLE, occurring in only 2%-30% of patients. Among these cases, the association of SLE with auto- immune hepatitis (AIH) is rare, with only a few cases being documented

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro

60. Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis

Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis RESEARCH Open Access Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis Teresa Schleker 1 , Eva-Maria Jacobsen 1 , Benjamin Mayer 2 , Gudrun Strauss 1 , Klaus-Michael Debatin 1 and Carsten Posovszky 1,3* Abstract Background: Children (...) with inflammatory bowel disease (IBD) or autoimmune hepatitis (AIH) are at risk for severe infections. This is partially a result of their chronic disease condition but, moreover, a side effect of their immunosuppressive therapy. Currently, vaccinations with live vaccines are regarded as contraindicated under immunosuppressive therapy, mainly because of concerns about side effects and a lack of data showing an adequate immune reaction. As there is no systematic study on the individual immunoreactivity under immunosuppressive

Molecular and cellular pediatrics2018 Full Text: Link to full Text with Trip Pro